奥拉帕尼联合帕博利珠单抗二线治疗广泛期小细胞肺癌的疗效
本研究纳入21例一线标准化疗后进展或复发的广泛期小细胞肺癌患者,比较奥拉帕尼联合帕博利珠单抗与帕博利珠单抗单药的疗效与安全性。联合组中位无进展生存期显著优于单药组(5.93 vs 3.53个月,P=0.036),客观有效率和总生存期差异无统计学意义,不良反应可耐受。
要点
- 联合组中位PFS为5.93个月,单药组为3.53个月,差异有统计学意义(P=0.036)。
- 联合组客观有效率为45.5%,单药组为10.0%,差异无统计学意义(P=0.149)。
- 转移灶数目、铂类敏感性和LDH水平显著影响联合治疗的有效率。
核心结论
- 奥拉帕尼联合帕博利珠单抗二线治疗广泛期小细胞肺癌初步显示较好疗效,安全性可耐受。
研究设计与样本
- 研究纳入2017年3月至2019年10月一线标准化疗后进展或复发的SCLC患者21例,联合组11例,单药组10例。
- 联合组接受奥拉帕尼300mg口服每日2次联合帕博利珠单抗200mg静脉滴注每3周1次,单药组接受帕博利珠单抗200mg静脉滴注每3周1次。
主要发现
- 联合组和单药组客观有效率分别为45.5%和10.0%(P=0.149),疾病控制率分别为81.8%和70.0%(P=0.635)。
- 联合组和单药组中位无进展生存时间分别为5.93和3.53个月(P=0.036),中位总生存时间分别为10.43和8.43个月(P=0.063)。
- 转移灶数目(P=0.006)、铂类敏感性(P=0.036)和乳酸脱氢酶水平(P=0.022)显著影响联合治疗的有效率。
关键数值与推荐
- 联合组和单药组不良反应发生率分别为90.9%和70.0%(P=0.311)。
- Ⅲ级及以上骨髓抑制发生率分别为36.4%和10.0%(P=0.311),胃肠道反应分别为9.1%和10.0%(P=1.000),其他免疫相关不良反应分别为18.2%和30.0%(P=1.000)。
临床怎么用
- 对于40~80岁广泛期小细胞肺癌患者,二线可考虑奥拉帕尼联合帕博利珠单抗方案。
- 联合治疗时需关注骨髓抑制等不良反应,尤其是Ⅲ级及以上骨髓抑制。
局限性
- 本研究为单中心小样本初步研究,样本量21例,结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To compare the efficacy and safety of olaparib in combination with pembrolizumab with pembrolizumab alone in second-line treatment for patients with extensive stage-small cell lung cancer (ES-SCLC) whose ages ranged from 40 to 80 years. Methods: From March 2017 to October 2019, 21 patients with progressed or relapsed small cell lung cancer after standard first line treatment were enrolled in this study. The olaparib/pembrolizumab group (n=11) was treated by olaparib 300mg twice per day combined with pembrolizumab 200mg once every 3 weeks, while pembrolizumab group was treated by pembrolizumab alone. Results: The objective response rate (ORR) of olaparib/pembrolizumab group and pembrolizumab group were 45.5% and 10.0%, respectively (P=0.149), and the disease control rate (DCR) were 81.8% and 70.0% (P=0.635). The median progression-free survival (PFS) were 5.93 months and 3.53 months (P=0.036), the median overall survival (OS) were 10.43 months and 8.43 months (P=0.063). The adverse reaction incidences of all grades were 90.9% and 70.0% (P=0.311), and the incidences of grade Ⅲ-Ⅴ including myelosuppression were 36.4% and 10.0% (P=0.311), gastrointestinal reaction were 9.1% and 10.0%, (P=1.000) and other immune-related adverse events were 18.2% and 30.0% (P=1.000). Further analysis showed the metastatic number (P=0.006), platinum sensitivity (P=0.036) and LDH level (P=0.022) significantly affected the ORR of olaparib/pembrolizumab therapy. Conclusion: Our preliminary study indicates that olaparib combined with pembrolizumab is an efficient and safe second-line treatment therapy for patients with ES-SCLC. 目的: 分析40~80岁广泛期小细胞肺癌(SCLC)患者接受二线奥拉帕尼联合帕博利珠单抗治疗以及帕博利珠单抗单药治疗的疗效和安全性。 方法: 选取2017年3月至2019年10月就诊于解放军总医院的一线标准化疗方案后进展或复发的SCLC患者21例,联合组接受奥拉帕尼(300 mg口服,每日2次)联合帕博利珠单抗(200 mg静脉滴注,每3周1次)治疗;单药组接受帕博利珠单抗(200 mg静脉滴注,每3周1次)治疗。 结果: 联合组和单药组患者的客观有效率分别为45.5%和10.0%(P=0.149),疾病控制率分别为81.8%和70.0%(P=0.635),中位无进展生存时间分别为5.93和3.53个月(P=0.036),中位总生存时间分别为10.43和8.43个月(P=0.063)。联合组和单药组患者的不良反应发生率分别为90.9%和70.0%(P=0.311),Ⅲ级及以上不良反应包括骨髓抑制(36.4%和10.0%,P=0.311)、胃肠道反应(9.1%和10.0%,P=1.000)和其他免疫相关不良反应(18.2%和30.0%,P=1.000)。多因素分析显示,转移灶数目(P=0.006)、铂类敏感性(P=0.036)和乳酸脱氢酶水平(P=0.022)为影响患者联合用药疗效的独立因素。 结论: 帕博利珠单抗联合奥拉帕尼初步显示较好的疗效,安全性可耐受,或可成为SCLC患者二线治疗方案的选择。.
引用
- Wu ZZ, Zhang SJ, Hu Y, et al. [Efficacy of olaparib combined with pembrolizumab in second-line treatment for extensive-stage small cell lung cancer]. Zhonghua Zhong Liu Za Zhi. 2020. PMID: 32842449. doi:10.3760/cma.j.cn112152-20200319-00226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。